MCRB - Seres Therapeutics - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

MCRB is currently covered by 6 analysts with an average price target of $123.82. This is a potential upside of $116.36 (1559.79%) from yesterday's end of day stock price of $7.46.

Seres Therapeutics's activity chart (see below) currently has 43 price targets and 49 ratings on display. The stock rating distribution of MCRB is 73.33% BUY, 13.33% HOLD and 13.33% SELL.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 39% with an average time for these price targets to be met of 74.4 days.

Highest price target for MCRB is $15, Lowest price target is $6, average price target is $87.

Most recent stock forecast was given by KEAY NAKAE from CHARDAN CAPITAL on 08-May-2025. First documented stock forecast 22-Oct-2015.

Currently out of the existing stock ratings of MCRB, 11 are a BUY (73.33%), 2 are a HOLD (13.33%), 2 are a SELL (13.33%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Hold

$6

$-1.46 (-19.57%)

$25

10 days ago
(08-May-2025)

1/5 (20%)

$-0.96 (-13.79%)

39

Sell

$15

$7.54 (101.07%)

$480

2 months 4 days ago
(14-Mar-2025)

3/3 (100%)

$1.2 (8.70%)

131

Buy

6 months 4 days ago
(14-Nov-2024)

0/3 (0%)

$101.2 (85.19%)

Sell

$140

6 months 24 days ago
(24-Oct-2024)

0/1 (0%)

$11.2 (8.70%)

Buy

$240

$232.54 (3117.16%)

$720

1 years 10 months 22 days ago
(26-Jun-2023)

4/8 (50%)

$132 (122.22%)

281

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is MCRB (Seres Therapeutics) average time for price targets to be met?

On average it took 74.4 days on average for the stock forecasts to be realized with a an average price target met ratio 39

Which analyst has the current highest performing score on MCRB (Seres Therapeutics) with a proven track record?

MARK BREIDENBACH

Which analyst has the most public recommendations on MCRB (Seres Therapeutics)?

Mark Breidenbach has 1 price targets and 6 ratings on MCRB

Which analyst is the currently most bullish on MCRB (Seres Therapeutics)?

Gbola Amusa with highest potential upside - $592.54

Which analyst is the currently most reserved on MCRB (Seres Therapeutics)?

Keay Nakae with lowest potential downside - -$1.46

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?